Our top pick for
Alexander's Inc is a reit-retail business based in the US. Alexanders shares (ALX) are listed on the NYSE and all prices are listed in US Dollars. Alexanders employs 70 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$286.40|
|52-week range||$218.39 - $298.50|
|50-day moving average||$266.26|
|200-day moving average||$272.05|
|Wall St. target price||$300.00|
|Dividend yield||$18 (6.41%)|
|Earnings per share (TTM)||$13.43|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-20)||2.94%|
|1 month (2021-09-27)||8.67%|
|3 months (2021-07-27)||1.46%|
|6 months (2021-04-27)||2.65%|
|1 year (2020-10-26)||15.90%|
|2 years (2019-10-25)||-16.19%|
|3 years (2018-10-26)||326.26|
|5 years (2016-10-26)||386.07|
Valuing Alexanders stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Alexanders's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Alexanders's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 21x. In other words, Alexanders shares trade at around 21x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Alexanders's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $106.9 million.
The EBITDA is a measure of a Alexanders's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$207.1 million|
|Operating margin TTM||35.44%|
|Gross profit TTM||$110.7 million|
|Return on assets TTM||3.26%|
|Return on equity TTM||31.95%|
|Market capitalisation||$1.5 billion|
TTM: trailing 12 months
There are currently 61,853 Alexanders shares held short by investors – that's known as Alexanders's "short interest". This figure is 4.2% down from 64,594 last month.
There are a few different ways that this level of interest in shorting Alexanders shares can be evaluated.
Alexanders's "short interest ratio" (SIR) is the quantity of Alexanders shares currently shorted divided by the average quantity of Alexanders shares traded daily (recently around 22993.680297398). Alexanders's SIR currently stands at 2.69. In other words for every 100,000 Alexanders shares traded daily on the market, roughly 2690 shares are currently held short.
However Alexanders's short interest can also be evaluated against the total number of Alexanders shares, or, against the total number of tradable Alexanders shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Alexanders's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Alexanders shares in existence, roughly 10 shares are currently held short) or 0.0179% of the tradable shares (for every 100,000 tradable Alexanders shares, roughly 18 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Alexanders.
Find out more about how you can short Alexanders stock.
Dividend payout ratio: 1.05% of net profits
Recently Alexanders has paid out, on average, around 1.05% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 6.3% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Alexanders shareholders could enjoy a 6.3% return on their shares, in the form of dividend payments. In Alexanders's case, that would currently equate to about $18 per share.
While Alexanders's payout ratio might seem low, this can signify that Alexanders is investing more in its future growth.
Alexanders's most recent dividend payout was on 19 August 2021. The latest dividend was paid out to all shareholders who bought their shares by 5 August 2021 (the "ex-dividend date").
Alexanders's shares were split on 27 December 1970.
Over the last 12 months, Alexanders's shares have ranged in value from as little as $218.3864 up to $298.4973. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Alexanders's is 0.6005. This would suggest that Alexanders's shares are less volatile than average (for this exchange).
Alexander's, Inc. is a real estate investment trust which has seven properties in the greater New York City metropolitan area. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.